In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Invitrogen China

Division of Thermo Fisher Scientific Inc.

Latest From Invitrogen China

Biomarkers and Beyond: Learning from Iressa – when and how to develop companion diagnostics

James Wade looks back over the path to market taken by one of AstraZeneca's oncology drugs and outlines some key lessons for pharmaceutical companies developing personalised cancer therapies. This article is part of Scrip's Biomarkers and Beyond analysis. For more articles, data and multimedia features exploring the role of biomarkers in the future of the pharmaceutical industry, visit

Cancer Japan

Hycult Biotech subsidiary appoints executive director

Mr Dino DiCamillo has been appointed executive director of Hycult Biotech Inc, the newly-incorporated US subsidiary of immunology and cell biology biotech company Hycult Biotech BV. Mr DiCamillo is currently president and CEO of Percorso Life Sciences, a consultancy organisation for life science companies focused on the North American market; he has also held presidential and leadership roles at Advanced Research Technologies, Alfa Wassermann Proteomics, Invitrogen and Dynal Biotech Inc.

Gene Logic appoints Norrie Russell as president

Gene Logic, part of the Indian genomics services company, Ocimum Biosolutions, has appointed Dr Norrie Russell as president. Dr Russell, who comes with more than 30 years of experience in drug discovery, has previously held leadership positions with NovaRx, Invitrogen, Aviva Biosciences and Lynx Therapeutics. He has also worked for AstraZeneca, where he was global head, biological science and technology.

Market Insight - Biotech targets Alzheimer's biomarkers, but fresh incentives needed

The buzz around personalised medicine points to a potentially lucrative market for robust biomarkers that will lead the way to more effective targeted therapies. Stefan Fritsch examines the use of genetic and serum- and urine-based biomarkers in the diagnosis of Alzheimer's disease and the factors driving pharma industry interest.

Neurology Norway
See All

Company Information